PRAME: A Potential New Target for Kidney Cancer Treatment

What is it about?

This research discusses a study investigating PRAME (Preferentially expressed antigen in melanoma) expression in renal cell carcinoma (RCC). PRAME, a protein with limited normal expression but overexpressed in many cancers, has become a promising immunotherapeutic target. The study aimed to evaluate PRAME expression in RCC using tissue microarrays and validated antibodies. Despite previous studies showing some PRAME expression in RCC, this comprehensive analysis found no PRAME expression in 285 primary RCC tumour samples, including clear cell and non-clear cell subtypes. This contrasts with positive PRAME expression observed in some RCC cell lines, melanoma, and non-small cell lung cancer samples. The findings suggest that PRAME may not be a suitable immunotherapeutic target for RCC, contrary to its potential in other cancer types.

Featured Image

Why is it important?

This research is significant because it provides a comprehensive evaluation of PRAME expression in renal cell carcinoma (RCC), a potential target for immunotherapy. As current immunotherapies for RCC have limitations, identifying new targetable antigens is crucial for developing alternative treatment strategies. The study's findings challenge previous assumptions about PRAME expression in RCC and highlight the importance of thorough validation of potential therapeutic targets before clinical development. Key Takeaways: 1. PRAME Absence in RCC: The study demonstrates a complete absence of PRAME expression across a large cohort of 285 primary RCC tumour samples, contradicting previous smaller studies and suggesting that PRAME may not be a suitable target for RCC immunotherapy. 2. Methodological Robustness: The research utilizes multiple validation techniques, including Western blotting, immunohistochemistry, and comparison with known positive and negative controls, enhancing the reliability of the findings. 3. Implications for Therapy Development: The results emphasize the need for careful validation of potential therapeutic targets in specific cancer types, as expression patterns may vary significantly between different malignancies and even between cell lines and primary tumours of the same cancer type.